Last reviewed · How we verify
Iocide Oral Rinse
At a glance
| Generic name | Iocide Oral Rinse |
|---|---|
| Also known as | Iocide Oral Rinse - once daily 30 second rinse for 24 weeks |
| Sponsor | Biomedical Development Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Iocide Oral Rinse Against Gingival Inflammation (PHASE2)
- Dose-Response Study of Iocide Oral Rinse (PHASE2)
- Exploratory Study of Iocide Oral Rinse in a Diabetic Population (PHASE1)
- Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
- Clinical Research Study Efficacy of a Prototype Oral Rinse (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iocide Oral Rinse CI brief — competitive landscape report
- Iocide Oral Rinse updates RSS · CI watch RSS
- Biomedical Development Corporation portfolio CI